The NICHE-2 Study Discussion with Dr. Myriam Chalabi

from Oncology Brothers: Practice-Changing Cancer Discussions · host Oncology Brothers

The NICHE-2 study offered neoadjuvant immune checkpoint inhibition in locally advanced MMR-deficient colon cancer patients, resulting in a major pathologic response in 95% of patients and 67% pCR. In discussion with the lead author, Dr. Myriam Chalabi - Medical Oncologist at the Netherlands Cancer Institute.   Website: http://www.oncbrothers.com/ Twitter: https://twitter.com/oncbrothers Contact us at [email protected]

Episode metadata supplied by the publisher feed · Published Jan 16, 2023

Embed this episode

Attribution link and audio player

NOW PLAYING

The NICHE-2 Study Discussion with Dr. Myriam Chalabi

0:00 17:48

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Oncology Brothers: Practice-Changing Cancer Discussions?

This episode is 17 minutes long.

When was this Oncology Brothers: Practice-Changing Cancer Discussions episode published?

This episode was published on January 16, 2023.

Can I download this Oncology Brothers: Practice-Changing Cancer Discussions episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!